Navigation Links
Breast milk may provide a personalized screen of breast cancer risk
Date:4/4/2011

ORLANDO, Fla. Breast cancer risk can be assessed by examining the epithelial cells found in breast milk, according to preliminary study results presented at the AACR 102nd Annual Meeting 2011, held April 2-6.

This screening method has the potential to provide a personalized assessment of breast cancer risk, said lead researcher Kathleen F. Arcaro, Ph.D., associate professor of veterinary and animal sciences at the University of Massachusetts Amherst. Given that roughly 80 percent of women give birth, this screen would also cover a large percentage of the female population.

Arcaro and colleagues collected breast milk samples from about 250 women who were scheduled for or who had a breast biopsy. The women submitted fresh samples, which were processed within 24 hours of expression; they provided samples from both breasts.

The researchers recruited about 90 percent of their study population from the Love/Avon Army of Women, which registers women who are willing to participate in breast cancer research. The American Association for Cancer Research is the scientific partner in this effort.

Once researchers received the samples, they isolated the epithelial cells (the potentially cancerous cells) in the breast milk. Then they isolated the DNA to look for epigenetic signals (attachment of methyl groups to DNA), which are the signals that tell the body those genes that should be expressed. These signals were then compared with breast cancer risk assessed using the biopsy results.

Arcaro and colleagues analyzed three genes: RASSF1, GSTP1 and SFRP1. "More than 35 genes have been shown to be methylated in breast cancer," she said.

Of the 104 women with a non-proliferative (low-risk) lesion, results showed no difference in the average epithelial DNA methylation of their biopsied breast vs. non-biopsied breast for RASSF1 and GSTP1. For SFRP1, however, the average methylation was higher in the biopsied breast. Importantly, among the women whose biopsies revealed cancer, there was a significant increase in average RASSF1 methylation in the biopsied breast vs. non-biopsied breast. Although the sample size in this study is small, "it's sufficient to tell us that we can use the cells in breast milk to assess breast cancer risk," Arcaro said, and additional studies are needed to expand the number of genes. Long-term studies are currently underway with about 80 percent of the original participants enrolled in follow-up.

Arcaro hopes that someday every woman who delivers a baby in a hospital will be screened for breast cancer via breast milk. "We'll take a little sample of colostrum, and we'll tell her how her breasts are doing," she said. "It's totally noninvasive, potentially inexpensive and really accurate."


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
4. For Some Breast Cancer Patients, Shorter Radiation Works Well
5. Short-term radiation therapy successful on breast cancer
6. Few Women at High Risk for Breast Cancer Take Tamoxifen
7. Hormone May Prevent Aggressive Breast Cancer
8. MSU researcher linking breast cancer patients with alternative therapies
9. MRI May Not Add Value to Routine Breast Cancer Care
10. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
11. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... ... weight management program at Women’s Excellence will help patients lose weight and keep ... exam. The specialists at Women's Excellence will measure BMI, body fat composition, ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... nurses and supply chain professionals, will hold their first Northeast Regional AHVAP Meeting. ... Bundles.” , “Increasingly, supply chain and value analysis professionals have a ‘seat ...
(Date:3/27/2017)... ... March 27, 2017 , ... Sodium determination is ... complicated and require expert user knowledge. In a live webinar on April 11th ... simplified, yet highly accurate, determination of sodium. , It has long been known ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... with opioids alone responsible for over 33,000 of the 52,404 drug-related deaths in ... Bill (AB) 1512, which proposes a tax on prescription opioids to fund drug ...
(Date:3/25/2017)... ... March 25, 2017 , ... Getting earned media coverage meaningful for ... , All through the year, Garden Media aims to provide material helpful to ... influencers and pitching client’s key messages to gain coveted media placements, Garden ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... and BOSTON , March 27, ... global pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of innovative therapies based upon tetracycline ... of sarecycline for the treatment of moderate to ... endpoints. Sarecycline is a once-daily, oral, narrow spectrum ...
(Date:3/27/2017)... Calif. , March 27, 2017  Impax Laboratories, ... has appointed Paul M. Bisaro as Impax,s ... the Company,s Board, effective March 27, 2017. Mr. Bisaro ... served as Interim President and Chief Executive Officer since ... of generic and branded pharmaceutical experience, Mr. Bisaro, 56, ...
(Date:3/27/2017)... -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing ... children, today reported financial results for the fourth ... and provided an update on its corporate activities. ... during the fourth quarter of 2016 through the ... study, and with our lead development candidate, PRX-OTC, ...
Breaking Medicine Technology: